Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00543725




Registration number
NCT00543725
Ethics application status
Date submitted
11/10/2007
Date registered
15/10/2007
Date last updated
1/04/2016

Titles & IDs
Public title
TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
Scientific title
A Phase III, Randomized, Double-blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects.
Secondary ID [1] 0 0
TMC278-TIDP6-C215
Secondary ID [2] 0 0
CR002704
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
HIV Infections 0 0
HIV-1 0 0
Condition category
Condition code
Infection 0 0 0 0
Acquired immune deficiency syndrome (AIDS / HIV)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - TMC278
Treatment: Drugs - efavirenz

Active comparator: 002 - efavirenz 600 mg tablet once daily for 96 weeks

Experimental: 001 - TMC278 25 mg tablet once daily for 96 weeks


Treatment: Drugs: TMC278
25 mg tablet once daily for 96 weeks

Treatment: Drugs: efavirenz
600 mg tablet once daily for 96 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48
Timepoint [1] 0 0
Week 48
Secondary outcome [1] 0 0
Number of Participants With Virological Response (Intent-to-Treat - Snapshot, <50 Copies Per mL) at Week 48
Timepoint [1] 0 0
Week 48
Secondary outcome [2] 0 0
Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 96
Timepoint [2] 0 0
Week 96
Secondary outcome [3] 0 0
Number of Participants With Virological Response (Intent-to-Treat - Snapshot, <50 Copies Per mL) at Week 96
Timepoint [3] 0 0
Week 96
Secondary outcome [4] 0 0
Number of Participants With Virological Response (Observed, <50 Copies/mL) at Last On-Treatment Visit (Post-Week 96).
Timepoint [4] 0 0
Variable, ranging from 3 months up to maximum 18 months for TMC278 and 12 months for Efavirenz
Secondary outcome [5] 0 0
Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies Per mL) at Week 48
Timepoint [5] 0 0
Week 48
Secondary outcome [6] 0 0
Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies Per mL) at Week 96
Timepoint [6] 0 0
Week 96
Secondary outcome [7] 0 0
Mean Change From Baseline to Week 48 and Week 96 in Absolute and Relative CD4+ Cell Counts (Using Imputed Data)
Timepoint [7] 0 0
Baseline, Week 48, and Week 96
Secondary outcome [8] 0 0
Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure
Timepoint [8] 0 0
Week 96

Eligibility
Key inclusion criteria
* Patient with documented HIV-1 infection
* Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to screening
* Patient's HIV-1 plasma viral load at screening is > 5,000 HIV-1 RNA copies/mL (assayed by RNA PCR standard specimen procedure)
* Patient's virus is sensitive to the 2 nucleoside/nucleotide reverse transcriptase inhibitors chosen for treatment
* Patient agrees not to start ART before the baseline visit
* Patient is HLA-B*5701 negative in case abacavir is included in the patient's treatment regimen.
Minimum age
18 Years
Maximum age
99 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Previous use of ANY ARV drug for ANY length of time
* Any documented evidence of NNRTI resistance associated mutations in patient's HIV
* Category C AIDS defining illness, except, Stable Kaposi Sarcoma Wasting syndrome if not progressive
* Pneumocystis carinii pneumonia (PCP) that is considered not cured
* Active TB
* Allergy or hypersensitivity to study or background ARTs
* Specific grade 3 or 4 toxicity
* Kidney impairment: calculated creatinine clearance <50 ml/min

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2012
Sample size
Target
Accrual to date
Final
680
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Darlinghurst
Recruitment hospital [2] 0 0
- Prahran
Recruitment hospital [3] 0 0
- Surry Hills
Recruitment postcode(s) [1] 0 0
- Darlinghurst
Recruitment postcode(s) [2] 0 0
- Prahran
Recruitment postcode(s) [3] 0 0
- Surry Hills
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
District of Columbia
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
Belgium
State/province [14] 0 0
Antwerpen
Country [15] 0 0
Belgium
State/province [15] 0 0
Brussels
Country [16] 0 0
Belgium
State/province [16] 0 0
Gent
Country [17] 0 0
Belgium
State/province [17] 0 0
Leuven
Country [18] 0 0
Brazil
State/province [18] 0 0
Campinas
Country [19] 0 0
Brazil
State/province [19] 0 0
Distrito Barao Geraldo-Campina
Country [20] 0 0
Brazil
State/province [20] 0 0
Pinheiros
Country [21] 0 0
Brazil
State/province [21] 0 0
Recife
Country [22] 0 0
Brazil
State/province [22] 0 0
Sao Paulo
Country [23] 0 0
Canada
State/province [23] 0 0
Alberta
Country [24] 0 0
Canada
State/province [24] 0 0
British Columbia
Country [25] 0 0
Canada
State/province [25] 0 0
Manitoba
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
Chile
State/province [28] 0 0
Providencia
Country [29] 0 0
Chile
State/province [29] 0 0
Santiago
Country [30] 0 0
China
State/province [30] 0 0
Beijing
Country [31] 0 0
China
State/province [31] 0 0
Guangzhou
Country [32] 0 0
China
State/province [32] 0 0
Shanghai
Country [33] 0 0
Costa Rica
State/province [33] 0 0
San Jose
Country [34] 0 0
France
State/province [34] 0 0
Clamart
Country [35] 0 0
France
State/province [35] 0 0
Le Kremlin Bicetre
Country [36] 0 0
France
State/province [36] 0 0
Montpellier
Country [37] 0 0
France
State/province [37] 0 0
Paris
Country [38] 0 0
Germany
State/province [38] 0 0
Berlin
Country [39] 0 0
Germany
State/province [39] 0 0
Essen
Country [40] 0 0
Germany
State/province [40] 0 0
Frankfurt
Country [41] 0 0
Germany
State/province [41] 0 0
Hamburg
Country [42] 0 0
Germany
State/province [42] 0 0
Hannover
Country [43] 0 0
Germany
State/province [43] 0 0
Köln
Country [44] 0 0
Germany
State/province [44] 0 0
Mannheim
Country [45] 0 0
India
State/province [45] 0 0
Chennai
Country [46] 0 0
India
State/province [46] 0 0
Nagpur
Country [47] 0 0
Mexico
State/province [47] 0 0
Guadalajara N/A
Country [48] 0 0
Mexico
State/province [48] 0 0
Mexico City
Country [49] 0 0
Panama
State/province [49] 0 0
Panama City N/A
Country [50] 0 0
Panama
State/province [50] 0 0
Panama
Country [51] 0 0
Portugal
State/province [51] 0 0
Porto
Country [52] 0 0
Puerto Rico
State/province [52] 0 0
San Juan
Country [53] 0 0
Russian Federation
State/province [53] 0 0
Moscow N/A
Country [54] 0 0
Russian Federation
State/province [54] 0 0
Saint-Petersburg
Country [55] 0 0
Russian Federation
State/province [55] 0 0
Smolensk
Country [56] 0 0
Russian Federation
State/province [56] 0 0
Voronezh
Country [57] 0 0
South Africa
State/province [57] 0 0
Bloemfontein
Country [58] 0 0
South Africa
State/province [58] 0 0
Cape Town
Country [59] 0 0
South Africa
State/province [59] 0 0
Dundee
Country [60] 0 0
South Africa
State/province [60] 0 0
Johannesburg
Country [61] 0 0
South Africa
State/province [61] 0 0
Pretoria N/A
Country [62] 0 0
South Africa
State/province [62] 0 0
Westdene Johannesburg Gauteng
Country [63] 0 0
Spain
State/province [63] 0 0
Barcelona N/A
Country [64] 0 0
Spain
State/province [64] 0 0
Barcelona
Country [65] 0 0
Spain
State/province [65] 0 0
Elche
Country [66] 0 0
Spain
State/province [66] 0 0
Madrid
Country [67] 0 0
Thailand
State/province [67] 0 0
Bangkok
Country [68] 0 0
United Kingdom
State/province [68] 0 0
London
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Tibotec Pharmaceuticals, Ireland
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Tibotec Pharmaceuticals, Ireland Clinical Trial
Address 0 0
Tibotec Pharmaceuticals, Ireland
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00543725